Articles From: Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes to Mercury® Wins RSPA Gold for Best Processor


Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes.
Sign-up for Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes investment picks
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today issued its 2013 global corporate responsibility report.
Sign-up for Merck Publishes 2013 Global Corporate Responsibility Report investment picks
WHITEHOUSE STATION, N.J. , Sept.
Sign-up for Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Sign-up for Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy investment picks
NEW YORK (MarketWatch) -- Shares of Merck (MRK) rose 1.1% in premarket trade after the drug giant reported second-quarter profit of $2 billion, or 68 cents a share, up from $906 million, or 30 cents a share, in the same period a year ago.
Sign-up for Merck shares rise in premarket trade as profit, sales beat forecasts investment picks
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today provided the following statement regarding the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices’ (ACIP’s) updated pneumococcal vaccine recommendations for adults 65 years of age and older.
Sign-up for Merck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults investment picks
2014/9/12
By Monica Houston-Waesch German pharmaceutical group Merck KGaA (MRK.XE) said Friday it will discontinue the clinical development program of its Tecemotide drug to treat lung cancer.
Sign-up for Merck to End Clinical Development of Lung Cancer Drug Tecemotide investment picks
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2014 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Monday, Oct.
Sign-up for Merck to Hold Third-Quarter 2014 Sales and Earnings Conference Call on October 27 investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.
Sign-up for Merck to Participate at the Morgan Stanley Global Healthcare Conference investment picks
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 – 30.
Sign-up for Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company’s Investigational Anti-PD-1 Antibody, at ESMO 2014 investment picks
"Speaking Up" is Vital, Given the Significant Impact of the Disease on Women WHITEHOUSE STATION, N.J. , July 17, 2014 /PRNewswire/ -- Merck (NYSE: MRK) , known as MSD outside the United States and Canada , today announced that Maria Davis – a music industry promoter and HIV advocate – and Positive Women's Network – USA (PWN- USA ) – are joining its national HIV education campaign, I Design.
Sign-up for Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Network - USA to Encourage Women Living with HIV to be "Vocal" about their Treatment investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company’s investigational anti-PD-1 antibody, for the treatment of advanced melanoma.
Sign-up for Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously known as MK-7655), the company’s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track status.
Sign-up for Merck’s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA investment picks
LOS ANGELES , July 28, 2014 /PRNewswire/ -- Mercury General Corporation (NYSE: MCY) reported today for the second quarter of 2014: Consolidated Highlights Three Months Ended June 30, Change Six Months Ended June 30, Change 2014 2013 $ % 2014 2013 $ % (000's except per-share amounts and ratios) Net premiums written (1) $ 698,759 $ 665,479 $ 33,280 5.0
Sign-up for Mercury General Corporation Announces Second Quarter Results and Declares Quarterly Dividend investment picks
LOS ANGELES , July 7, 2014 /PRNewswire/ -- Mercury General Corporation (NYSE: MCY) reported that on Monday, July 28, 2014 , the Company will release results for its second quarter ended June 30 , 2014.
Sign-up for Mercury General Corporation To Report Second Quarter Results On July 28, 2014 investment picks
2014/7/16
Mercury StoreCard now enables local merchants to offer their customers a gift, reward, mobile payments and promotions card all in one product.
Sign-up for Mercury StoreCard™ Now Available investment picks
CHELMSFORD, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (Nasdaq:MRCY) ( www.mrcy.com ), a leading provider of affordable, commercially developed, open sensor processing systems and services for critical commercial, defense and intelligence applications, announced the appointment of Brian Perry as President of its Mercury Defense Systems (MDS) subsidiary.
Sign-up for Mercury Systems Appoints Brian Perry President of Mercury Defense Systems Subsidiary investment picks
CHELMSFORD, Mass., Sept.
Sign-up for Mercury Systems Appoints Gerald M. Haines II Executive Vice President and Chief Financial Officer investment picks
CHELMSFORD, Mass., June 16, 2014 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (Nasdaq:MRCY) ( www.mrcy.com ), a best-of-breed provider of commercially developed, open sensor and Big Data processing systems for critical commercial, defense and intelligence applications, announced that its Mercury Defense Systems subsidiary has received a $1.5 million order from the U.S. Navy for advanced Digital RF Memory (DRFM) jammers to support both U.S. Navy and U.S. Air Force requirements.
Sign-up for Mercury Systems Receives $1.5 Million Order From US Navy for DRFM Jammers investment picks
CHELMSFORD, Mass., Sept.
Sign-up for Mercury Systems Receives $2 Million Order From US Navy for DRFM Jammers investment picks
CHELMSFORD, Mass., Aug.
Sign-up for Mercury Systems Receives $27 Million Order for Airborne Sensor Processing Application investment picks
CHELMSFORD, Mass., June 30, 2014 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (Nasdaq:MRCY) ( www.mrcy.com ), a best-of- breed provider of commercially developed, open sensor and Big Data processing systems for critical commercial, defense and intelligence applications, announced it received $3.4 million in orders from a leading defense prime contractor for integrated microwave assemblies (IMAs) for an airborne electronic warfare (EW) application.
Sign-up for Mercury Systems Receives $3.4 Million in Orders for Integrated Microwave Assemblies for Electronic Warfare Application investment picks
CHELMSFORD, Mass., July 7, 2014 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (Nasdaq:MRCY) ( www.mrcy.com ), a leading provider of affordable, commercially developed, open sensor processing systems and services for critical commercial, defense and intelligence applications, announced it received $4.4 million in orders from a leading defense prime contractor for advanced radio frequency (RF) microwave tuner and intermediate frequency (IF) products for a naval signals intelligence (SIGINT) application.
Sign-up for Mercury Systems Receives $4.4 Million in Orders for Advanced RF Products for Signals Intelligence Application investment picks
Company's Manteca, Calif., Facility Ranks Among Top 8% of All Facilities Reviewed CHELMSFORD, Mass., June 23, 2014 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (Nasdaq:MRCY) ( www.mrcy.com ), a best-of-breed provider of commercially developed, open sensor and Big Data processing systems for critical commercial, defense and intelligence applications, announced that its Mercury Commercial Electronics facility in Manteca, Calif., received a Superior security rating in a recent vulnerability assessment conducted by the Defense Security Service (DSS). This Superior rating, the highest level awarded to cleared defense contractors by DSS, is the company's sixth Superior rating overall and a significant milestone for this facility, which previously had earned a Commendable rating.
Sign-up for Mercury Systems Receives Sixth Superior Security Rating by U.S. Defense Security Service investment picks
Fourth quarter operating results from continuing operations include: CHELMSFORD, Mass., August 5, 2014 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (Nasdaq:MRCY) ( www.mrcy.com ), a leading provider of affordable, commercially developed, open sensor processing systems and services for critical commercial, defense and intelligence applications, reported operating results for its fourth quarter and fiscal 2014 which ended June 30, 2014.
Sign-up for Mercury Systems Reports Fourth Quarter and Fiscal 2014 Results investment picks
CHELMSFORD, Mass., Aug.
Sign-up for Mercury Systems to Present at the Jefferies 2014 Global Industrials Conference investment picks
CHELMSFORD, Mass., July 21, 2014 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (Nasdaq:MRCY) ( www.mrcy.com ), a leading provider of affordable, commercially developed, open sensor processing systems and services for critical commercial, defense and intelligence applications, will release its fourth quarter and fiscal 2014 financial results after the market close on Tuesday, August 5, 2014.
Sign-up for Mercury Systems to Report Fourth Quarter and Fiscal Year 2014 Financial Results and Host Conference Call on August 5, 2014 investment picks
Innovative technology enables fastest OpenVPX processing subsystems for defense and aerospace applications CHELMSFORD, Mass., Sept.
Sign-up for Mercury Systems' Breakthrough Interconnect Technology Delivers the Fastest Embedded Switch Fabrics investment picks
CHELMSFORD, Mass., Sept.
Sign-up for Mercury's New OpenVPX Processing Module is First in Industry to Break the Teraflop Barrier investment picks
Mercury Payment Systems was awarded the Gold Vendor of Excellence award as an Outstanding Provider of Electronic Payments / Financing at the Retail Solutions Provider Association’s (RSPA) RetailNOW 2014 convention and expo in Orlando.
Sign-up for Mercury® Wins RSPA Gold for Best Processor investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes to Mercury® Wins RSPA Gold for Best Processor
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices